Release time：Jun 11, 2023
The "Osteoporosis Diagnosis and Treatment Summit Forum and National Launch of Mailishu" hosted by Mabwell was successfully held in Taizhou, Jiangsu on June 10, 2023. MAILISHU is the world’s second biosimilar drug to Denosumab approved for marketing and is indicated for postmenopausal women with osteoporosis at high risk of fractures.
Government representatives, including Mr. Ding Zhiqiang, Deputy Secretary of the Party Working Committee and Director of the Administrative Committee of Taizhou Medical High-tech Zone, Deputy Secretary of the Party Committee and District Mayor of Gaogang District, and Mr. Wu Xiang, Deputy Secretary of the Party Working Committee and Director of the Administrative Committee of Taizhou Modern Pharmaceutical High Tech Industrial Park, experts and scholars including Professor Xia Weibo of Peking Union Medical College Hospital of the Chinese Academy of Medical Sciences, Mr. Zhao Lidong, General Manager of Sinopharm Logistics Co., Ltd., Mr. Xu Yi, President of Taizhou Branch of China Merchants Bank, as well as Dr. Liu Datao, Co-founder and CEO of Mabwell, Mr. Li Han, Vice President of Mabwell, and Dr. Ding Mansheng, Executive Deputy General Manager of T-mab, a wholly-owned subsidiary of Mabwell, jointly attended the launching ceremony of MAILISHU.
Mr. Ding Zhiqiang, Deputy Secretary of the Party Working Committee and Director of the Administrative Committee of Taizhou Medical High-tech Zone, Deputy Secretary of the Party Committee and District Mayor of Gaogang District, said: "Mabwell has always adhered to its original intention and maintained its determination, working hand in hand with China Medical City to provide strong impetus for the high-quality development of the biopharmaceutical industry in China Medical City. We hope that Mabwell will take the launch of this product as an opportunity to continue to focus on deep cultivation and development in the field of segmented products, and create core heavyweight products with global competitiveness, accelerating the industrialization process of China Medical City and promoting the high-quality development of the biopharmaceutical industry. China Medical City will always uphold the service concept of 'professional, focused, and dedicated', and strive to create the best business environment for enterprise development."
Professor Xia Weibo of Peking Union Medical College Hospital of the Chinese Academy of Medical Sciences said, "It has been demonstrated in accordance with the relevant research guidelines and regulatory requirements, based on the principles of comparative and progressive development, and through an evaluation of pharmaceutical, non-clinical, and clinical comparison results that MAILISHU has the overall similarity in terms of quality, safety, and efficacy to the Prolia®. As a high-quality biosimilar drug to Denosumab, MAILISHU can increase the convenience and compliance of treatment for patients. We hope that the launch of MAILISHU will benefit more Chinese patients with osteoporosis."
Mr. Zhao Lidong, General Manager of Sinopharm Logistics Co., Ltd., said: "We are very grateful for the trust that Mabwell has placed in Sinopharm Logistics by assigning the nationwide logistics storage and distribution of MAILISHU to us. Sinopharm Logistics, with comprehensive storage and transportation network and professional service team, will assist Mabwell in expanding sales and reaching more end-users in China, and together we will provide safe and reliable drugs for patients."
Dr. Liu Datao, co-founder and CEO of Mabwell, said, "Osteoporosis is characterized by high incidence, high disability, and low treatment rates, for which there is broad clinical demand in China and even globally. After the approval of MAILISHU, our Taizhou industrialization base is fully committed to providing high-quality drugs for patients as soon as possible to improve their quality of life. At the same time, we are actively expanding the indications of MAILISHU and have reached strategic cooperation with multiple countries, hoping to benefit more patients with osteoporosis worldwide."
At this Osteoporosis Diagnosis and Treatment Summit Forum, several experts also delivered exciting academic lectures and interactive discussions on topics of the research progress, clinical medication, treatment strategies, diagnostic and treatment standards of osteoporosis.